Trial Profile
The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses, Airway Inflammation and Aspects of Airway Remodeling in Subjects With Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma (HDM)-Allergic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs FP 025 (Primary)
- Indications Allergic asthma; Asthma
- Focus Proof of concept; Therapeutic Use
- Sponsors Foresee Pharmaceuticals
- 11 Sep 2023 According to Foresee Pharmaceuticals Media Release, data from this study were presented at the European Respiratory Society (ERS) International Congress 2023
- 11 Sep 2023 Results presented in the Foresee Pharmaceuticals Media Release.
- 11 Sep 2023 According to Foresee Pharmaceuticals Media Release, Primary endpoint (The primary end point of this study is to determine the effect of FP-025 versus placebo on the allergen (HDM)-induced late asthmatic response (LAR) in subjects with clinically stable, mild allergic asthma and blood eosinophilia) has been met.